We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Committee Reverses Policy on Pfizer’s Sutent for Renal Cancer
NICE Committee Reverses Policy on Pfizer’s Sutent for Renal Cancer
February 5, 2009
A UK advisory board recommends Pfizer’s Sutent as a first-line treatment for certain renal cancer patients, reversing an earlier decision on the drug.